Contributions of rare and common variation to early-onset and atypical dementia risk

Authors:
Carter A. Wright1,2, Jared W. Taylor1, Meagan Cochran1, James M.J. Lawlor1, Belle A. Moyers1, Michelle D. Amaral1, Zachary T. Bonnstetter1, Princess Carter3, Veronika Solomon3, Richard M. Myers1, Marissa Natelson Love3, David S. Geldmacher3, Sara J. Cooper1, Erik D. Roberson3, J. Nicholas Cochran1,3

Affiliations:
1HudsonAlpha Institute for Biotechnology, Huntsville, Alabama 35806, USA; 2University of Alabama in Huntsville, Huntsville, Alabama 35899, USA; 3Alzheimer’s Disease Center, Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA

Correspondence: ncochran@hudsonalpha.org, eroberson@uabmc.edu

Abstract
We collected and analyzed genomic sequencing data from individuals with clinician-diagnosed early-onset or atypical dementia. Thirty-two patients were previously described, with sixty-eight newly described in this report. Of those sixty-eight, sixty-two patients reported Caucasian, non-Hispanic ethnicity and six reported as African American, non-Hispanic. Fifty-three percent of patients had a returnable variant. Five patients harbored a pathogenic variant as defined by the American College of Medical Genetics criteria for pathogenicity. A polygenic risk score was calculated for Alzheimer’s patients in the total cohort and compared to the scores of a late-onset Alzheimer’s cohort and a control set. Patients with early-onset Alzheimer’s had higher non-APOE polygenic risk scores than patients with late onset Alzheimer’s, supporting the conclusion that both rare and common genetic variation associate with early-onset neurodegenerative disease risk.

Introduction
Dementia affects over 55 million people worldwide, nine percent of these patients are under age 65 (Dua et al. 2017). Rare variants in three genes, PSEN1, PSEN2, and APP, are associated with autosomal dominant early-onset Alzheimer’s disease (EOAD), however they only explain about 10% of genetic cases (Stoychev et al. 2019). The use of genome sequencing allows identification of rare variants not included in some targeted gene panel testing, as well as variation that is the purview of future research such as including non-coding variants and variants in novel risk loci. In our previous study we reported on the use of genome sequencing in 32 individuals with early-onset and/or atypical dementia and described several pathogenic variants associated with disease, including combinations of disease-associated risk variants. Our previous work confirmed the value of genetic assessment and identified contributing genetic variation for over half of the cohort (Cochran et al. 2019).

The American College of Medical Genetics (ACMG) criteria was used to assess pathogenicity and pathogenic/likely pathogenic variants were returned. Additional
criteria to return variants included: 1) any variant with a disease-established odds ratio of >2 described in multiple reports, which we defined as an “established risk variant”, 2) presence of one or two APOE ε4 alleles in a patient with EOAD or atypical dementia likely due to EOAD, or 3) one strong report with a disease-associated odds ratio >2 with replication included in the study design, which we defined as a “likely risk variant.”

In this report we also assessed the dementia risk related to common variation for the enrolled patients by calculating polygenic risk scores. Our results highlight the complex genetic etiology of early-onset and/or atypical dementia.

**Results**

Here we report on 68 additional patients collected as a continuation of the previously published cohort. For each patient with clinician-diagnosed early-onset or atypical dementia, we collected and analyzed genomic sequencing data. We identified returnable, primary findings for 53% of patients *(Fig. 1A, Table 1)*. Including the initial 32 probands described by Cochran, et al. in our previous report, a total of 100 patients have been enrolled through the Brain Aging and Memory Clinic at the University of Alabama at Birmingham *(Fig. 1B)*.
Table 1. Variant Table.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Chr.</th>
<th>HGVS DNA</th>
<th>HGVS Protein</th>
<th>Variant Type</th>
<th>Predicted Effect</th>
<th>dbSNP ID</th>
<th>CADD Score</th>
<th>gnomAD Allele Counts</th>
</tr>
</thead>
<tbody>
<tr>
<td>APOE</td>
<td>19</td>
<td>NM_000041.3:c.388T&gt;C</td>
<td>p.(Cys130Arg)</td>
<td>SNV</td>
<td>Missense</td>
<td>rs429358</td>
<td>16.65</td>
<td>23,875</td>
</tr>
<tr>
<td>APOE</td>
<td>19</td>
<td>NM_000041.3:c.526C&gt;T</td>
<td>p.(Arg176Cys)</td>
<td>SNV</td>
<td>Missense</td>
<td>rs7412</td>
<td>26</td>
<td>31,094</td>
</tr>
<tr>
<td>SORL1</td>
<td>11</td>
<td>NM_003105.6:c.3856C&gt;T</td>
<td>p.(Arg1286Cys)</td>
<td>SNV</td>
<td>Missense</td>
<td>NA</td>
<td>29.3</td>
<td>1</td>
</tr>
<tr>
<td>PRNP</td>
<td>20</td>
<td>NM_183079.3:c.416T&gt;C</td>
<td>p.(Ile139Thr)</td>
<td>SNV</td>
<td>Missense</td>
<td>NA</td>
<td>18.98</td>
<td>0</td>
</tr>
<tr>
<td>SORL1</td>
<td>11</td>
<td>NM_003105.6:c.6194A&gt;T</td>
<td>p.(Asp2065Val)</td>
<td>SNV</td>
<td>Missense</td>
<td>NA</td>
<td>28.8</td>
<td>347</td>
</tr>
<tr>
<td>ABCA7</td>
<td>19</td>
<td>NM_019112.3:c.4416+1G&gt;T</td>
<td>NA</td>
<td>Splice</td>
<td></td>
<td>NA</td>
<td>26.3</td>
<td>6</td>
</tr>
<tr>
<td>PAH</td>
<td>12</td>
<td>NM_000277.3:c.117C&gt;G</td>
<td>p.(Phe39Leu)</td>
<td>SNV</td>
<td>Missense</td>
<td>rs62642926</td>
<td>25.6</td>
<td>13</td>
</tr>
<tr>
<td>PAH</td>
<td>12</td>
<td>NM_000277.3:c.194T&gt;C</td>
<td>p.(Ile65Thr)</td>
<td>SNV</td>
<td>Missense</td>
<td>rs75193786</td>
<td>27.2</td>
<td>45</td>
</tr>
<tr>
<td>GRN</td>
<td>17</td>
<td>NM_002087.3:c.26C&gt;A</td>
<td>p.(Ala9Asp)</td>
<td>SNV</td>
<td>Missense</td>
<td>rs63751243</td>
<td>23.6</td>
<td>0</td>
</tr>
<tr>
<td>MAPT</td>
<td>17</td>
<td>NM_005910.5:c.1216C&gt;T</td>
<td>p.(Arg406Trp)</td>
<td>SNV</td>
<td>Missense</td>
<td>rs63750424</td>
<td>23.5</td>
<td>4</td>
</tr>
<tr>
<td>PSEN1</td>
<td>14</td>
<td>NM_000021.4:c.236C&gt;T</td>
<td>p.(Ala79Val)</td>
<td>SNV</td>
<td>Missense</td>
<td>rs63749824</td>
<td>26.8</td>
<td>5</td>
</tr>
<tr>
<td>PSEN2</td>
<td>1</td>
<td>NM_000447.3:c.712C&gt;T</td>
<td>p.(Leu238Phe)</td>
<td>SNV</td>
<td>Missense</td>
<td>rs367855127</td>
<td>25.3</td>
<td>3</td>
</tr>
<tr>
<td>PSEN2</td>
<td>1</td>
<td>NM_000447.3:c.211C&gt;T</td>
<td>p.(Arg71Trp)</td>
<td>SNV</td>
<td>Missense</td>
<td>rs140501902</td>
<td>22.4</td>
<td>513</td>
</tr>
<tr>
<td>ABCA7</td>
<td>19</td>
<td>NM_019112.3:c.4010C&gt;T</td>
<td>p.(Thr1337Ile)</td>
<td>SNV</td>
<td>Missense</td>
<td>NA</td>
<td>23.9</td>
<td>0</td>
</tr>
<tr>
<td>TSC2</td>
<td>16</td>
<td>NM_000548.5:c.3846_3855delCTCCAAGGA</td>
<td>p.(Ser1282Arg_delIC1283-G1285)</td>
<td>Deletion</td>
<td>INDEL</td>
<td>NA</td>
<td>NA</td>
<td>0</td>
</tr>
<tr>
<td>SCN5A</td>
<td>3</td>
<td>NM_198056.2:c.673C&gt;T</td>
<td>p.(Arg225Trp)</td>
<td>SNV</td>
<td>Missense</td>
<td>rs199473072</td>
<td>23.4</td>
<td>12</td>
</tr>
<tr>
<td>KCTD17</td>
<td>22</td>
<td>NM_001282684.2:c.299G&gt;C</td>
<td>p.(Gly100Ala)</td>
<td>SNV</td>
<td>Missense</td>
<td>NA</td>
<td>34</td>
<td>2</td>
</tr>
<tr>
<td>SORL1</td>
<td>11</td>
<td>NM_003105.6:c.2711G&gt;A</td>
<td>p.(Arg904Gln)</td>
<td>SNV</td>
<td>Missense</td>
<td>NA</td>
<td>31</td>
<td>20</td>
</tr>
</tbody>
</table>

All variants were observed in the heterozygous state except for APOE (NM_000041.3:c.388T>C, p.(Cys130Arg)), which was observed in both the heterozygous and homozygous state. APOE (NM_000041.3:c.526C>T, p.(Arg176Cys)) is also noted here, because confirmation of its absence along with APOE (NM_000041.3:c.388T>C, p.(Cys130Arg)) indicates the APOE ε4 allele. (HGVS) Human Genome Variation Society, (dbSNP) Single Nucleotide Polymorphism Database, (gnomAD) Genome Aggregation Database, (CADD) Combined Annotation Dependent Depletion, (SNV) single-nucleotide variant.
Clinical Presentation and Family History

Of the 68 additional patients described here, 40 patients were male and 28 patients were female. Ethnicity was self-reported of which 62 patients reported Caucasian and 6 reported African American. All patients reported non-Hispanic ethnicity. One patient reported age of onset in the 80s, 4 in 70s, 23 in 60s, 29 in 50s, 10 in 40s, and one in 30s (Supplemental Table 1). The nine patients with an age of onset older than 65 had moderate to strong family histories of dementia.

We generated a family history score for each patient that is a derivative of the scoring system first used by Goldman et al. (Goldman et al. 2005). The modified Goldman Score was generated as follows: (1) At least three people in two generations affected with EOAD, Frontotemporal dementia (FTD), ALS, corticobasal degeneration (CBD), Parkinson's disease (PD), or progressive supranuclear palsy (PSP) with one person being a first-degree relative of the other two; (1.5) Criteria matching (1) but with late-onset Alzheimer disease (LOAD) instead of EOAD; (2) At least two relatives with dementia, FTD, ALS, CBD, PD, or PSP and criteria for autosomal dominant inheritance were not met; (3) A single affected first or second degree family member with early-onset dementia or at least two with FTD, ALS, CBD, PD, mild cognitive impairment (MCI), or PSP; (3.5) A single affected first or second degree family member with late-onset dementia, FTD, ALS, CBD, PD, MCI, or PSP; and (4) non contributory family history or unknown family history. We classified patients with a family history score of 1 or 1.5 as strong family history, 2, 3, or 3.5 as moderate family history, and those with a score of 4 had no contributory or known family history. All family history scores are included in Supplemental Table 1. We note that the researchers do not have the ability to identify patients based on IDs, as the key is kept at the clinical enrollment site.

Genomic Analyses

Variants were evaluated using ACMG criteria (Richards et al. 2015) for pathogenicity and the ACMG evidence codes for all pathogenic variants are detailed in the Supplemental ACMG Pathogenicity Evidence Details.

C9orf72 Expansion Testing

We tested for pathogenic G4C2 hexanucleotide expansion at the C9orf72 locus, which is associated with FTD and ALS, either as described in Cochran, et al. (Cochran et al. 2019) (using a separately obtained test from GeneDx) or, for samples that were sequenced with a PCR-free genome, using ExpansionHunter (Dolzhenko et al. 2017). All patients in this cohort expansion of 68 were negative for C9orf72 repeat expansion.

Pathogenic Diagnoses

Two Pathogenic Variants in PAH in a Patient with Phenylketonuria

A patient with phenylketonuria (PKU) with onset in their early 40s had two pathogenic variants in PAH (NM_000277.3:c.117C>G, p.(Phe39Leu)) and (NM_000277.3:c.194T>C, p.(Ile65Thr)). Segregation analysis of the family showed the PAH variants were in trans. Both variants have been submitted to ClinVar as pathogenic for PKU, by multiple submitters (VCV000000605.15 and VCV000000636.18). PKU is an autosomal recessive disease that can cause brain dysfunction due to increased phenylalanine concentrations.
Adult-onset PKU is rare and can present with symptoms of dementia and parkinsonism making it difficult to quickly diagnose. If diagnosed correctly PKU can be treated with a phenylalanine restricted diet (Tufekcioglu et al. 2016; Rosini et al. 2014).

**A Pathogenic GRN Variant in a Family with FTD**
A patient with an onset of MCI in their early 50s had a pathogenic variant in GRN (NM_002087.3:c.26C>A, p.(Ala9Asp)). This variant is absent from gnomAD and has been reported by several laboratories as pathogenic in ClinVar (VCV000016013.12). This variant segregates with two affected family members. We classified this variant as pathogenic as additional studies have shown this variant to segregate with FTD (Mukherjee et al. 2008; Shankaran et al. 2008).

**A Rare MAPT Variant in Five Early-onset Alzheimer’s Disease Patients**
Two patients with EOAD (one patient also exhibited signs of FTD) with age of onset in their 50s have a pathogenic variant in MAPT (NM_005910.5:c.1216C > T, p.(Arg406Trp)). This rare variant has a minor allele frequency of 0.000016% and was reported by several laboratories as pathogenic in ClinVar (VCV000014247.18). In our previous study (Cochran et al. 2019), we identified three patients with this variant in MAPT. The presence of the same rare variant in a total of five patients enrolled at the same clinic suggests a common ancestry is likely (Fig. 2A). We inferred the relatedness of patients using KING (Manichaikul et al. 2010) and determined a kinship coefficient for each pair of relationships and determined that three probands have a kinship coefficient of 0.06 or greater, reaching the criteria for third degree relation (Fig. 2B). The other values did not reach the kinship coefficient of 0.06 criteria but were near that threshold and might reflect a more distant relationship.

**A PSEN1 Variant in a Patient with Mild Cognitive Impairment**
An individual with symptoms of MCI and a strong family history of AD had a pathogenic variant in PSEN1 (NM_000021.4:c.236C>T, p.(Ala79Val)). Onset of symptoms began in their 60s and multiple affected family members had onset in 60s. This pathogenic variant has been previously reported in ClinVar (VCV000018157.5) in patients with AD. Variants in PSEN1 are the most common cause of autosomal dominant familial Alzheimer’s disease (Kelleher and Shen 2017).

**Compound Heterozygous Risk Factors**

**APOE ε4 Risk Factors**
The APOE ε4 allele is the most common strong risk factor for Alzheimer’s disease (AD), the most common form of dementia. Patients carrying one APOE ε4 allele are noted as APOE ε4 heterozygous and those carrying two alleles are noted as APOE ε4 homozygous. We identified 25 (36%) patients with at least one APOE ε4 allele. Several of them, described here, also carried other risk variants.

**APOE ε4 with SORL1 Risk Variants**
A patient presenting with symptoms of EOAD with onset in their early 50s and a strong family history of AD had one APOE ε4 allele, a “likely risk variant” in SORL1
(NM_003105.6:c.3856C>T, p.(Arg1286Cys)), and a variant in PRNP (NM_183079.3:c.416T>C, p.(Ile139Thr)) (returned as a VUS). Pathogenic PRNP variants are typically missense variants and are associated with prion diseases (Piazza et al. 2020). To our knowledge the c.416T>C variant in PRNP has not been previously published or reported in gnomAD (Karczewski et al. 2020). This variant was returned as a VUS because the family history of a prion disease could not be determined. The c.3856C>T SORL1 variant has a minor allele frequency of 0.0007% and is predicted damaging by PolyPhen-2 (Adzhubei et al. 2010) and SIFT (Ng and Henikoff 2003), with a Combined Annotation Dependent Depletion (CADD) (Kircher et al. 2014) score of 29. Loss-of-function SORL1 variant carriers are present at an odds ratio of ~4 compared to population databases (Raghavan et al. 2018). The odds ratio for LOF variants in this gene could be as high as 12.3 for AD and 27.5 for EOAD. For rare missense variants, the odds ratio could be as high as 3.14 for EOAD (Campion et al. 2019). Other similar variants in SORL1, in aggregate, are enriched in patients with early-onset dementia by at least 2 fold in comparison to individuals without dementia (Holstege et al. 2017).

Two patients in our study harbored one APOE ε4 allele and the same “likely risk variant” in SORL1 (NM_003105.6:c.6194A>T, p.Asp2065Val). This variant in the SORL1 gene has not been extensively described, to our knowledge. One of these two patients was diagnosed with EOAD, with an onset in their late 40s. The other enrolled patient harboring this variant presented with mild cognitive impairment that was amnestic in character with an age of onset in their 70s and a striking family history of dementia. This patient also had a rare variant in ECE2 (NM_001037324.2:c.1120C>T, p.(Arg374*)) that was not returned but had a CADD score of 39 and had a predicted effect of a stop gained. Variants in ECE2 have been implicated in Alzheimer’s disease risk, and variants in the peptidase domain were shown to impair enzymatic activity of ECE2 in Aβ degradation (Liao et al. 2020).

APOE ε4 Heterozygote with ABCA7 Risk Allele
An African American patient diagnosed with mild cognitive impairment with onset in their late 50s harbored an "established risk" loss-of-function splice variant in ABCA7 (NM_019112.3:c.4416+1G>T) and one APOE ε4 risk allele. The ABCA7 splice variant had a CADD score of 26 and is predicted to affect splicing by multiple splicing prediction tools (Pashaei et al. 2016; Jian et al. 2014). The c.4416+1G>T variant has been identified in gnomAD 6 times, however it has only been identified in African Americans. Variants in ABCA7 have been implicated as strong genetic predictors of AD in African Americans (Reitz et al. 2013) and have been associated with the progression and development of AD (Sinha et al. 2019). These variants likely contribute to the individual’s strong family history of AD.

Rare Variants of Uncertain Significance
In a patient with onset in their 50s and a EOAD diagnosis, we observed a VUS in PSEN2 (NM_000447.3:c.712C>T, p.(Leu238Phe)). This variant has a CADD of 25, is predicted damaging by PolyPhen-2 and MetaSVM (Kim et al. 2017), and has been previously classified as a VUS and once as likely pathogenic in Clinvar (VCV000448151.4). Hsu, et al. described this PSEN2 L238F variant as a potential AD
risk factor after identifying it in a patient diagnosed with EOAD that had several affected family members (Hsu et al. 2018). In another study, mouse neuroblastoma cells with this L238F variant had an increased Aβ42/40 ratio compared to wildtype cells which led to the classification for this variant as “probable pathogenic” (Hsu et al. 2020). An increased Aβ42/40 ratio is a predictor of amyloid-PET positivity in patients with Alzheimer’s disease (Amft et al. 2022).

A patient with EOAD had a variant in PSEN2 (NM_000447.3:c.211C>T, p.(Arg71Trp)) (returned as “likely risk”). Previous studies reported the odds ratio for this variant as 6.45 and 10.3 (Benitez et al. 2013; Cruchaga et al. 2012), suggesting that someone who has the variant is at increased risk to develop AD, but these reports suggest this variant alone is not enough to cause disease. Additionally, individuals who have AD and carry this variant have a significantly earlier age of onset than those who have AD and do not carry the variant (Cruchaga et al. 2012). This is consistent with our finding of EOAD in this patient.

One individual with AD with age of onset in their 50s had a rare variant in ABCA7 (NM_019112.3:c.4010C>T, p.(Thr117Ile)) (returned as a VUS) that has not been identified in gnomAD or published to our knowledge. Rare missense variants in ABCA7 have been previously reported to have an odds ratio of 1.6 and loss-of-function variants have an odds ratio of 2.2 for individuals with EOAD (Holstege et al. 2021). This individual met the missense criteria (allele frequency <1% and ‘moderate’ or ‘high’ variant effect predictor impact classification) described by Holstege, et al. We predict this rare variant to be damaging due to its CADD score (23.9) and computational evidence supporting its deleterious effect on the gene or gene product.

An individual diagnosed with moderate dementia with age of onset in their 60s had a rare deletion in TSC2 (NM_000548.5:c.3846_3855delCTCCAAGGA, p.(Ser1282Arg_delC1283–G1285)) (returned as a VUS). This individual also had a secondary finding: a pathogenic variant in SCN5A(NM_000335.4:c.673C>T, p.(Arg225XTrp)). This specific SCN5A variant has been reported to cause Brugada syndrome (Beckermann et al. 2014; Kapplinger et al. 2010). Brugada syndrome is an inherited cardiac arrhythmia condition and management includes prevention of cardiac arrest. The individual's sibling was reported to have died from cardiac arrest in their 60s.

A patient diagnosed with EOAD with age of onset in their 40s had a rare variant in KCTD17 (NM_001282684.2:c.299G>C, p.(Gly100Ala)) (returned as a VUS). This variant had a CADD of 34 and was predicted damaging due to the computational evidence supporting its deleterious effect on the gene or gene product. The c.299G>C variant in the KCTD17 gene was previously classified as a VUS for Myoclonus-dystonia by Invitae (Accession number SCV000932534.2 in ClinVar).

A patient diagnosed with moderate dementia with age of onset in the 50s had a rare variant in SORL1 (NM_003105.6:c.2711G>A, p.(Arg904Gln)) (returned as “likely risk”). As previously described above, SORL1 missense variants with a minor allele frequency
< 1x10^{-4} and multiple bioinformatic damaging predictions have a corresponding odds ratio of ~3 (Campion et al. 2019). This variant had a CADD of 31 and was predicted damaging by PolyPhen-2, MetaSVM, and PROVEAN (Choi and Chan 2015).

**Polygenic Risk Score**

A polygenic risk score (PRS) represents a statistical estimate of disease risk calculated by combining information about multiple risk variants throughout the genome. We sought to understand the contribution of common variation to AD risk in this cohort. Using the PRS generated by Cruchaga, et al. (Cruchaga et al. 2018), we computed a PRS for each proband in our study (Supplemental Table 2). We also calculated scores for 880 LOAD cases (818 ADSP, 62 UAB), 77 EOAD (UAB early-onset or atypical dementia) cases that are the focus of this study, and 5,179 healthy controls (5,043 ADSP, 136 other Alabama-based study). We calculated PRS for all individuals using two methods, one that incorporates APOE status and one that omits it. APOE is a strong known risk factor for AD, however when including it in the PRS there was not a significant different between dementia cohorts (Supplemental Fig. 1). We did observe differences in the PRS of these cohorts when APOE was excluded (Fig. 3). We observed that the median PRS of the UAB EOAD cohort was higher than the LOAD cohort upon APOE exclusion. These results are consistent with the possibility that APOE status alone could be a stronger association for LOAD; in contrast, though APOE remains a critical contributor to EOAD, additional deleterious genetic variation may be more likely to contribute to the emergence of an EOAD presentation. We also showed that the PRS in all AD cohorts was higher than our control cohort of unaffected individuals (Fig. 3). Since we combined two control cohorts and two LOAD cohorts we also compared the PRS of each cohort separately and did not observe any significant differences between control or LOAD groups (Supplemental Fig. 2). In the 42% of UAB EOAD patients with no returnable findings, we hypothesized that PRS might be higher than those patients with a known pathogenic variant due to the combination of multiple genetic factors contributing to dementia risk. That would indicate that perhaps common variation rather than rare variation were contributing to risk in these cases. However, in the UAB EOAD cohort we did not see a significant difference in PRS between patients with a returnable pathogenic variant based on genomic sequencing compared to those with no returnable variants (Supplemental Fig. 3).

Individuals with the strongest family history are more likely to have a returnable result (regardless of PRS), but 71% of non-Hispanic Caucasian patients with the strongest family history of early-onset or atypical dementia still do not have a known pathogenic mutation. This led us to consider if combinations of common variants can explain risk in these individuals. Indeed, there is a correlation where a more extensive family history of dementia is associated with significantly higher APOE– PRS, but there is no effect on APOE+ PRS (Supplemental Fig. 4).

African Americans have a higher prevalence of AD than Caucasians, however there are disparities in the amount of genetic data available from this population (Clark et al. 2022). The generation of polygenic risk scores are typically performed using Caucasian, non-Hispanic populations. As others have observed (Clark et al. 2022), we saw that
existing PRS do not capture variation contributing to AD risk in African Americans (Supplemental Fig. 5), pointing to the importance of developing ancestry-specific and/or ancestry adjusted PRS.

Discussion
Accumulation of amyloid-β protein in the brain is characteristic of Alzheimer’s disease and can occur many years before the onset of symptoms (Luckett et al. 2022). As a prominent example, APOE, the largest genetic risk factor for AD, has been associated with amyloid-β accumulation in the brain, therefore identifying genetic risk variants prior to symptom onset is critical for treatment decisions and potential enrollment in prevention trials. In this study, genome sequencing revealed variants contributing to dementia risk that would be missed by targeted panel testing, affirming the need for comprehensive genetic approaches. For example, MAPT variants are typically associated with FTD, however there have been multiple reports of MAPT variants in patients with AD (Cruts et al. 2012; Reed et al. 1997; Rademakers et al. 2003). Panels that are specific to AD do not include MAPT variants, thus this variant would not be detected. Whole genome sequencing provides a solution to this challenge. Some commercially available panels address this issue by assessing genes associated with multiple neurodegenerative diseases on the same panel. Six percent of our 100 patient cohort had variation in MAPT that contributes to AD risk, however in this cohort, we hypothesized that the five patients with the MAPT R406W variant likely shared common ancestry limiting the interpretation of the frequency of mutations in this gene leading to AD risk.

To better assess the risk of dementia patients with multiple contributory factors we calculated a PRS for individuals with early-onset or atypical dementia that was either definitively or most likely due to AD and late-onset AD, as well as a control cohort. The PRS we used was employed in a previous study (Cruchaga et al. 2018). Similar to Cruchaga, et al. we showed an increased PRS in patients with an earlier onset of disease when considering APOE– PRS, however we observed the opposite for APOE+ PRS. This points to the importance of further studies to clarify the applicability of LOAD PRS to EOAD, and suggests that EOAD-specific PRS could be informative as EOAD cohort sizes grow to a size that permits generation of a reliable EOAD-specific score. This trend held true when separating cohorts by ethnicity, however when applied to African American samples the PRS were lower compared to Caucasian samples with similar phenotypes and in fact African American patients with LOAD did not have a significantly different PRS than the controls. African Americans have twice the risk of developing AD as Caucasian individuals (Alzheimer’s disease facts and figures, 2020). Future studies generating PRS using genetic data from African Americans and other non-Europeans is necessary to more accurately determine the contribution of common variation in African American individuals, but the latest GWAS for African Americans with AD is still underpowered for this analysis, pointing to the critical nature of further study in this population (Kunkle et al. 2021).

In this study, we showed that multiple genetic factors, both rare and common, contribute to an individual’s dementia risk. Variants were not returned to many patients and this
could be because our cohort is limited by patient number, thus it is possible that a larger cohort would reveal small effects of PRS in patients with no returnable findings. Despite the limitation of patient number, we identified and returned variants that contribute to the genetic explanation of patients’ symptoms for more than half of the cohort. This study contributes to the body of work showing the value of comprehensive genetic testing in identifying variants contributing to early-onset dementia risk (Cochran et al. 2019; Huq et al. 2022) and highlights that both rare and common genetic variation can associate with early-onset and/or atypical dementia.

Methods

**C9orf72 Expansion Testing**
ExpansionHunter (Dolzhenko et al. 2019) was used to detect repeat expansions of C9orf72 for samples with PCR-free genomes (21 individuals). Prior to implementation of PCR-free genomes, C9orf72 expansions were assessed using a separate clinical test (GeneDx).

**Polygenic Risk Score**
PRS was calculated with and without APOE using PLINK 1.9 --score with the no-mean-imputation option. Odds ratios for the SNPs were collected from the IGAP study (Lambert et al. 2013), and a log base 2 transformation was used on the odds ratios. APOE risk was calculated through the use of artificial SNPs such that each SNP represented the combination of rs429358 and rs7412 alleles. The odds ratios for the PRS scores with APOE used odds ratios from Farrer et al. (Farrer et al. 1997) for APOE status (ε3/ε4, ε4/ε4, ε2/ε3, ε2/ε4, ε2/ε2) instead of each SNP independently.

The HudsonAlpha CSER study enrolled and sequenced children with an early-onset neurodevelopmental disorder (NDD) with symptoms such as intellectual disability, seizures, developmental delays, etc. Many of these children’s parents were also sequenced, and we used these parents as controls. While these individuals were ascertained as a result of having a child with an NDD, the parents themselves were generally healthy. In that context, it is important to note that the vast majority of the disease-associated variation found in the CSER study was either de novo (i.e., the disease-associated allele in the proband is absent from his/her parents), recessive (i.e., each parent was a heterozygous, unaffected carrier of a disease-associated allele), or X-linked (i.e., the proband is hemizygous for a disease-associated allele inherited from an unaffected heterozygous mother). To the extent that some of these parental individuals harbor symptoms and/or dominant or incompletely penetrant risk factors of NDDs, such conditions are phenotypically and genetically distinct from the neurodegenerative diseases we are studying here. Finally, we note that a small amount of phenotypic data was collected for each of these parents, and none of them were known to have a neurodegenerative disease at enrollment. Patients with a clinical diagnosis of FTD, CAA, MSA, PCA, CBS, white matter disease, progressive spastic dysarthria, or MS were excluded for polygenic risk score calculation.

**Genome Sequencing**
Genome sequencing was performed at the HudsonAlpha Institute for Biotechnology on the NovaSeq platform using paired end 150-base pair reads. Sequencing libraries were prepared by Covaris shearing, end repair, adapter ligation, and PCR using standard protocols. Library concentrations were normalized using KAPA qPCR prior to sequencing. All sequencing variants returned to patients were validated by Sanger in a CAP/CLIA laboratory.

**Data Processing and Quality Control**

Quality control included confirmation of each sample’s expected biological sex based on counts of chrX heterozygous variants. All samples were processed through a unified sequence alignment and variant calling pipeline. Variants were called with Strelka version 2.9.10. Sequence reads were aligned to GRCh38.p12 (with HudsonAlpha Clinical Sequencing Lab customized ALT mappings) using the Sentieon v201808.07 (Kendig et al. 2019) implementation of BWA-MEM (Li 2013) and command line option -M -K 10000000. BWakit was used for post-alt processing of the alternate contig alignments. Duplicate reads were marked and base quality scores were recalibrated with Sentieon v201808.07 using dbSNP v.146, Mills, and 1000G gold standard indels as training data. Variants were called on the hg38 primary contigs (chr1-chr22, chrX, chrY, chrM) using Strelka v2.9.10 (Kim et al. 2018) in germline single-sample analysis mode.

**Data Analysis**

Statistical analyses were conducted in R (version 3.6.1) using ggplot2 (version 3.3.6) (Wickham 2016).

Vcftools (version 0.1.16) (Danecek et al. 2011) was used for relationship inference analyses using the --relatedness2 command line option.

GraphPad Prism 9 (version 9.3.1) was used for plotting violin plots and ANOVA with Kruskal-Wallis tests performed in GraphPad were unpaired, non-parametric, two-tailed with 95% confidence interval.

**Genomic Analysis**

The HudsonAlpha-developed Codicem application was used to analyze and support the interpretation of the variant data (described elsewhere (Holt et al. 2019)). Simple filtering for population allele frequencies (i.e., gnomAD and TOPMed Bravo (NHLBI 2018)), in silico deleteriousness scores (i.e., CADD, PolyPhen-2, and SIFT), and gene lists relevant to the phenotype of interest would recapitulate our findings using any suitable software package or even by a command line interface. In addition to searching for single-nucleotide variants and small indels, we also searched for large copy-number variations using four callers (DELLY (Rausch et al. 2012), ERDS (Zhu et al. 2012), CNVnator (Abyzov et al. 2011), and BIC-seq2 (Xi et al. 2016)), but did not identify any relevant to patient phenotypes (including absence of APP duplications).

**Return of Results**

Results meeting criteria for return were delivered to patients by clinicians in the UAB Brain Aging and Memory Clinic through letters written by a genetic counselor. Letters
included information on the variant, associated disease, recurrence risk, and management recommendations. Patients were given the option to have a genetic counselor present for return of results via phone or videoconference or to follow up with a genetic counselor after delivery of results. Primary results were provided only to probands. Although a secondary result was identified in only one participant who was a patient, we did also offer nonpatient participants (family members) receipt of actionable secondary findings (ACMG SF v3.0) if such a result had been identified. Family members of patients that received diagnostic results were provided with information to seek out clinical genetic counseling and targeted testing for familial variants if they desired.

Patients were able to opt in to receiving secondary findings. To return secondary findings we followed the ACMG classification criteria. Secondary variants had to reach a classification of likely pathogenic or pathogenic and must be in a gene on the ACMG SF v3.0 list.

Additional Information
Data Access
Data from the first 32 participants enrolled in this study are deposited at NIAGADS under project NG00082 - UAB/HudsonAlpha Families with Neurodegenerative Diseases. Note to reviewers: data for all other participants as well as for participants in the UAB ADRC study (a subset of late-onset cases) will be deposited to NIAGADS and made publicly available as a prerequisite of acceptance of the manuscript. We are working on this data deposition currently.

We combined two cohorts of LOAD patients. One LOAD cohort was collected at UAB and a Global Diversity (Illumina product #20031816) plus NeuroBooster microarray was run on the samples. The other LOAD samples were from the Alzheimer's Disease Sequencing Project (ADSP) (NIAGIDS accession number: NG00067.v9). Control samples were from the HudsonAlpha CSER study (Bowling et al.), dbGap study accession number: phs001089.v3.p1) and from ADSP (NIAGIDS accession number: NG00067.v9).

Ethics Statement
This study was approved by UAB IRB protocol X161202004, “Evaluation of Genomic Variants in Patients with Neurologic Diseases.” All participants described provided explicit written consent for publication. Participants in the UAB LOAD set were approved via UAB IRB protocol #300000169, “UAB Alzheimer’s Disease Research Center/ Brain Aging and Memory in the South (BAMS) Study.”

Acknowledgements
We thank the Clinical Services Laboratory at HudsonAlpha for DNA isolations, library generation, quality control, and sequencing and the Codicem software development team at HudsonAlpha for genome analysis software. We thank Dr. Emily Gordon for her assistance with pedigree visualization. We also thank the Greg Cooper Lab, including
Drs. Michelle Thompson, Susan Hiatt, and Don Latner, for helpful discussions about variant interpretation.

Authors' Contributions

Funding
Funding for genomes sequenced at HudsonAlpha was generously provided by the Daniel Foundation of Alabama and donors to the HudsonAlpha Foundation Memory and Mobility Program. Additional funding was provided by NIH grant R00AG068271 (J.N.C.), and NIH grant 5P20AG068024 (E.D.R., D.S.G., M.N.L, J.N.C., and J.W.T.).

References


NHLBI UM. 2018. The NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. *BRAVO variant browser*.


Figure 1. Summary of genomic sequencing findings for the (A) 68 proband cohort and (B) all 100 enrolled probands including the 32 described in Cochran, et al. Patients carrying one APOE ε4 allele are noted as APOE ε4 Het. and those carrying two alleles are noted as APOE ε4 Hom. Patients carrying a risk allele in addition to one or two APOE ε4 allele are listed as APOE ε4 Het. or Hom. + risk. VUS = Variant of Uncertain Significance.
Figure 2. Evaluation of five probands with a MAPT R406W variant. (A) Pedigrees for the five probands with the MAPT variant. Probands are marked with arrow. Affected family members are solid pink. Patients 1-3 were identified in our previous study (Cochran et al., 2019). (B) Diagram showing the KING kinship coefficients between probands. Values in red denote third degree relatives. Figure was generated at biorender.com.
**Figure 3.** Violin plot comparing polygenic risk scores (PRS) of the UAB early-onset Alzheimer’s (UAB EOAD) cohort to patients with a late-onset Alzheimer’s (LOAD) cohort, and the control (Control) cohort. This PRS excludes APOE status. Only individuals with a self-reported ancestry of Caucasian, Non-Hispanic were included in this analysis. ANOVA with Kruskal-Wallis test was used to calculate adjusted p-values.